GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
The scale is the least interesting thing these drugs do. That statement would have sounded like marketing five years ago. The trial evidence has since made it defensible.
This is what the research actually establishes, and where the honest limits are.
Cardiovascular events
This is the strongest finding and the one that changed how these drugs are regarded.
The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled adults aged 45 and over with pre-existing cardiovascular disease and a BMI of 27 or above, but without diabetes.
Semaglutide reduced the incidence of cardiovascular death, non-fatal heart attack and non-fatal stroke compared with placebo.
That population matters. Previous cardiovascular findings came from diabetes trials, where benefit could be attributed to blood sugar control. SELECT removed diabetes from the equation.
Earlier evidence pointed the same way. REWIND, published in The Lancet, followed 9,901 people with type 2 diabetes on dulaglutide for a median 5.4 years, finding major adverse cardiovascular events in 594 cases against 663 on placebo. Most participants did not have established cardiovascular disease at enrolment, so the benefit extended to primary prevention.
LEADER found cardiovascular events in 13.0 percent on liraglutide against 14.9 percent on placebo.
Three large trials, three drugs, consistent direction.
Kidney outcomes
REWIND's companion analysis found reduced kidney outcomes alongside the cardiovascular benefit.
The plausible routes are better blood sugar control reducing diabetic kidney damage, lower blood pressure, and reduced filtration burden from weight loss itself.
Blood pressure and cholesterol
Both improve, and they improve early.
Blood pressure falls with weight reduction, frequently enough that existing antihypertensive medication needs reducing. Triglycerides fall. The overall lipid picture improves.
These are not incidental. High blood pressure and dyslipidaemia are among the main routes by which excess weight causes harm.
Blood sugar and diabetes prevention
The original purpose of the drug class, and it works.
For people with type 2 diabetes, HbA1c falls substantially. For people with prediabetes, progression to diabetes is reduced.
This matters particularly in South Asia, where type 2 diabetes prevalence is high and develops at lower BMI thresholds than in Western populations.
Sleep apnea
Obstructive sleep apnea is strongly weight-related. Fat around the neck and upper airway narrows it, and airway collapse during sleep follows.
Weight loss reduces severity, and improvement can be substantial. People frequently report better sleep quality, less daytime sleepiness and reduced snoring before the scale has moved dramatically.
Fatty liver
Metabolic dysfunction-associated steatotic liver disease, previously called non-alcoholic fatty liver disease, improves with weight loss.
This is particularly relevant in South Asian populations, where fatty liver occurs frequently and at lower body weights than in Western populations.
Joint pain and mobility
Mechanical rather than metabolic, and immediate.
Every kilogram lost reduces load through the knees and hips several times over during walking. People with knee osteoarthritis frequently report meaningful improvement, and the effect on daily mobility is often what patients value most.
Food noise
This one is subjective and consistently reported.
Many people describe constant background thinking about food that they had assumed was normal. Planning meals, thinking about the next one while eating, food occupying mental space throughout the day.
GLP-1 medication quietens that. People describe the mental relief as significant, sometimes more so than the weight change itself.
It is not measured in trials the way blood pressure is, but the consistency of the reports makes it worth naming.
The 5 to 10 percent point
This is the most practically useful fact in this article.
Most health benefits arrive at 5 to 10 percent weight reduction, not at a target weight.
Blood pressure, blood sugar, cholesterol, sleep apnea severity and fatty liver all improve meaningfully in that range. On a 90 kg person that is roughly 4.5 to 9 kg.
People frequently regard a 6 kg loss as failure because they wanted 25 kg. Medically, 6 kg is where a large share of the benefit sits.
Where the honest limits are
Not everything is established. Effects on addiction behaviours, mood and various conditions are being studied and are not settled. Preliminary findings should be read as preliminary.
Weight loss explains most of it. Where benefit is demonstrated, weight reduction accounts for much of it. Some findings suggest effects beyond what weight loss alone would predict, which is genuinely interesting and not fully explained.
Benefits require continued treatment. Weight regain after stopping is common, and cardiometabolic improvements largely revert alongside it.
These are trial populations. SELECT studied people with existing cardiovascular disease. Results do not automatically transfer to a healthy 30-year-old wanting to lose 8 kg.
What this changes about the decision
If you are weighing whether treatment is worth it, the scale is the wrong frame.
Someone with obesity plus hypertension, prediabetes and sleep apnea is potentially buying reduced risk of serious events, better sleep and improved mobility. Someone with a BMI of 31 and no other conditions is buying something more modest.
Physician-guided GLP-1 pathway support approaches this through the same appetite pathway, as a physician-reviewed sublingual supplement with medical review before dispatch. METASLIM™ is not semaglutide, tirzepatide or any pharmaceutical GLP-1 receptor agonist, and the trial results above describe those drugs rather than this product.
What transfers is the underlying principle rather than the trial figures. The health improvements above follow from weight reduction, and they begin at 5 to 10 percent regardless of how that reduction is achieved.
Before deciding anything, check your BMI and consider which of these conditions apply to you. That is a better basis for the decision than a target number.
Our guide to is weight loss medicine worth the cost works through that assessment, and the complete GLP-1 medication list covers the drugs themselves.
The summary
SELECT showed semaglutide reduced cardiovascular death, non-fatal heart attack and non-fatal stroke in people with obesity and cardiovascular disease but without diabetes.
REWIND and LEADER found consistent cardiovascular benefit, with REWIND also showing reduced kidney outcomes.
Blood pressure, cholesterol, blood sugar, sleep apnea, fatty liver and joint pain all improve.
Most benefits arrive at 5 to 10 percent weight reduction rather than at a target weight.
Reduced food noise is consistently reported and frequently valued more than the weight change.
Benefits largely revert if weight is regained after stopping.
See if you qualify for the program based on your conditions rather than a target weight.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.